Publications

2022

Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) Cream Demonstrates High Efficacy and Convenience in Skin of Color Patients with Plaque Psoriasis

 

Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer Gel in Patients With Molluscum Contagiosum

 

Berdazimer 10.3% Gel, a Nitric Oxide-Releasing Topical Medication for Molluscum Contagiosum, Triggers BOTE (Beginning Of The End) Inflammation and Accelerates Resolution

 

Clinical Development Program of Novel Topical Nitric Oxide Releasing Medication Berdazimer Gel 10.3% for the
Once-Daily Treatment of Molluscum Contagiosum

 

2021

SB206, a Nitric Oxide–releasing Topical Medication Induces the BOTE (Beginning-of-the-End) Sign and Molluscum Clearance

 

2020

A Nitric Oxide-releasing Topical Medication as a Potential Treatment Option for Atopic Dermatitis Through Antimicrobial and Anti-inflammatory Activity

 

2019

Efficacy and Tolerability of an Investigational Nitric Oxide-releasing Topical Gel in Patients With Molluscum Contagiosum: A Randomized Clinical Trial

 

NVN1000, a Novel Nitric Oxide-Releasing Compound, Inhibits HPV-18 Virus Production by Interfering with E6 and E7 Oncoprotein Functions

 

2018

A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis

Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections

 

A Phase 2 Controlled Study of SB206, a Topical Nitric Oxide-Releasing Drug for Extragenital Wart Treatment

 

2016

Results of a Phase 2, Randomized,Vehicle-Controlled Study Evaluating the Efficacy,Tolerability, and Safety of Daily or Twice Daily SB204 for the Treatment of Acne Vulgaris

NITRICIL™

Our Pipeline

Therapeutic Areas

Sign Up For Alerts